Comparing Therapies for Postmenopausal Osteoporosis Prevention and Treatment

2003 ◽  
Vol 37 (5) ◽  
pp. 711-724 ◽  
Author(s):  
Samantha F Eichner ◽  
Kimberly B Lloyd ◽  
Erin M Timpe
Keyword(s):  
Postmenopausal Osteoporosis ◽  
Osteoporosis Prevention ◽  
Prevention And Treatment

Tibolone for the prevention and treatment of postmenopausal osteoporosis

2003 ◽  
Author(s):  
A Cranney ◽  
S Rohekar ◽  
N Mnogma ◽  
T Towheed
Keyword(s):  
Postmenopausal Osteoporosis ◽  
Prevention And Treatment

Osteoporosis Prevention and Treatment

2008 ◽  
Vol 27 (4) ◽  
pp. 254-255
Author(s):  
Delores C. Schoen
Keyword(s):  
Osteoporosis Prevention ◽  
Prevention And Treatment

Exercise Therapy in Prevention and Treatment of Postmenopausal Osteoporosis: An Update

2015 ◽  
Vol 4 (1) ◽  
pp. 47-49
Author(s):  
Kumar Senthil P. ◽  
◽  
Adhikari Prabha ◽  
Jeganathan . ◽  
Kumar Anup ◽  
...  
Keyword(s):  
Postmenopausal Osteoporosis ◽  
Exercise Therapy ◽  
Prevention And Treatment

scholarly journals Consensus statement: osteoporosis prevention and treatment in Latin America—current structure and future directions

2018 ◽  
Vol 13 (1) ◽  
Author(s):  
Ben-Hur Albergaria ◽  
Monique Chalem ◽  
Patricia Clark ◽  
Osvaldo Daniel Messina ◽  
Rosa Maria R. Pereira ◽  
...  
Keyword(s):  
Latin America ◽  
Consensus Statement ◽  
Osteoporosis Prevention ◽  
Future Directions ◽  
Current Structure ◽  
Prevention And Treatment

scholarly journals SERMs in the prevention and treatment of postmenopausal osteoporosis: an update

2010 ◽  
Vol 54 (2) ◽  
pp. 200-205 ◽  
Author(s):  
Jaime Kulak Júnior ◽  
Carolina Aguiar Moreira Kulak ◽  
Hugh S. Taylor
Keyword(s):  
Estrogen Receptor ◽  
Postmenopausal Osteoporosis ◽  
Single Agent ◽  
Clinical Development ◽  
Target Tissue ◽  
New Approach ◽  
Estrogen Receptor Modulators ◽  
Receptor Modulator ◽  
Prevention And Treatment ◽  
Receptor Modulators

Selective estrogen receptor modulators (SERMs) have the ability to bind the estrogen receptor (ER) and are known to confer ER agonist or antagonist effects depending on the target tissue. A number of newer SERMs, including bazedoxifene, lasofoxifene and ospemifene, are currently under clinical development for the prevention and treatment of postmenopausal osteoporosis and for other indications. Although the possibility of developing a single agent that has all of the desired characteristics of an ideal SERM seems to be unlikely, progress in the clinical development of SERMs targeted to the ER suggests that these newer compounds may have attributes that represent an improvement relative to existing SERMs. A new approach to menopausal therapy is the tissue selective estrogen complex or the pairing of a selective estrogen receptor modulator with estrogens. Further investigation will help to clarify relative benefits/risks of novel SERMs in development within specific indications.

Sign in / Sign up

Export Citation Format

Share Document